Eli Lilly's tirzepatide is off FDA's shortage list
Eli Lilly's tirzepatide is off the FDA's shortage list: What it means for patients
Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.
Eli Lilly’s weight-loss drug no longer in shortage, FDA says
The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug Administration announced Wednesday.
US FDA to reconsider decision barring compounded versions of Lilly weight loss drug
The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders from selling their own versions of Eli Lilly's blockbuster weight loss and diabetes drugs.
Should Eli Lilly Investors Worry About This Unexpected FDA Move?
Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven major gains in recent times. And that's the company's weight loss drugs. Lilly sells the compound tirzepatide under two different names -- Mounjaro for type 2 diabetes and Zepbound for weight loss.
FDA is reconsidering its decision to take tirzepatide off its drug shortage list
Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications Mounjaro and Zepbound, the FDA said in a recent court filing.
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...
Can weight loss drugs get people back to work? Eli Lilly wants to find out
Eli Lilly (LLY) has partnered with the government of the United Kingdom to see if its blockbuster weight loss drug could help ...
Could Weight-Loss Drugs Help Get People Back to Work? The U.K. Wants to Find Out.
The British government announced a multimillion dollar pharmaceutical partnership with Eli Lilly, including a trial that will ...
STAT5d
As Eli Lilly, compounders battle over weight loss drugs, patients are caught in the middle
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
FDA To Reassess Ban On Cheaper, Compounded Versions of Eli Lilly Weight Loss Drugs
The FDA resolved the shortage of Eli Lilly's tirzepatide, but may revisit allowing compounding pharmacies to make copies, ...
Lilly weight-loss drug copycats dealt blow as shortage ends
Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., ...
Everyday Health15h
Are Compounded Weight Loss Drugs on Their Way Out?
The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...
The Australian Financial Review7d
Weight loss wars: a century on, the battle heats up
Meanwhile, Eli Lilly is fighting off competition from copycat weight-loss drugs and other drug developers entering the lucrative field, and coming under increasing pressure from politicians ...
Eli Lilly to invest $364M in UK trial linking obesity drug to employment
The company has committed £279 million ($364 million) to support national efforts aimed at reducing obesity, a critical ...